目的调查帕金森病（PD）患者中异动症及症状波动的发生率、分布情况以及影响因素。方法详细记录患者资料，并进行统一帕金森病评分量表（UPDRS）、Hoehn＆Yahn（H—Y）分级评分。根据UPDRS1V记录患者有无异动症及症状波动。结果122例患...目的调查帕金森病（PD）患者中异动症及症状波动的发生率、分布情况以及影响因素。方法详细记录患者资料，并进行统一帕金森病评分量表（UPDRS）、Hoehn＆Yahn（H—Y）分级评分。根据UPDRS1V记录患者有无异动症及症状波动。结果122例患者接受左旋多巴治疗，疗程至少6个月。其中15例（12．3％）合并异动症，41例（33．6％）合并症状波动。异动症的独立影响因素为：发病年龄（OR=0．907，P〈0．01）和左旋多巴总量（95％ CI 1．000～1．004，OR=1．002，P〈0．05）；症状波动的独立影响因素为：发病年龄（OR=0．922，P〈0．05），接受左旋多巴治疗的时间（OR=1．234，P〈0．05），左旋多巴总量（95％ CI 1．002—1．008，OR=1．005，P〈0．01）和H—Y分级（OR=1．869，P〈0．05）。结论本组患者异动症及症状波动的发生率均低于欧洲调查结果，每日左旋多巴总量是异动症及症状波动的独立影响因素。添加其他药物辅助治疗而减少左旋多巴用量，可以减少运动并发症的发生。展开更多
目的分析健康人直立于不同厚度海绵垫时姿势特征的变化,探讨本体觉受到不同程度干扰时的姿势平衡改变。方法 30例健康人分别站立于坚硬平板和不同厚度的海绵垫,海绵厚度依次从1到5块,每块厚度4.7 cm。每种站立平面下,均睁眼和闭眼各站立...目的分析健康人直立于不同厚度海绵垫时姿势特征的变化,探讨本体觉受到不同程度干扰时的姿势平衡改变。方法 30例健康人分别站立于坚硬平板和不同厚度的海绵垫,海绵厚度依次从1到5块,每块厚度4.7 cm。每种站立平面下,均睁眼和闭眼各站立30 s。应用姿势描记仪记录人体直立时足底压力中心(center of pressure,COP)晃动的相关参数,包括总轨迹长、平均速度、单位面积轨迹长、外周面积、实效值面积、矩形面积。结果所有参数在睁眼和闭眼条件下均有随海绵垫厚度的增加而变化趋势(睁眼时 F 值为9.14～107.18,闭眼时 F 值为32.19～144.35,P 值均<0.0001),除单位面积轨迹长呈减少趋势外,其余参数均为增加趋势;对各参数在不同海绵垫间的差异进行比较,无统计学意义的情况有:①总轨迹长和速度:睁眼及闭眼时,4和5块之间;②单位面积轨迹长:睁眼时,0和1、1和3、2和3、3和4、4和5块之间;闭眼时,3和4、3和5、4和5块之间;③外周面积:睁眼时2和3、3和4、4和5块之间;闭眼时,3和4、3和5、4和5块之间;④实效值面积和矩形面积:睁眼时2和3、4和5块之间;闭眼时,3和4、3和5、4和5块之间。其余比较差异均有统计学意义(P<0.05)或极显著统计学意义(P<0.01)。结论在一定范围内,随着海绵垫厚度增加,直立其上的人体本体觉受到的干扰程度加剧,其姿势稳定性逐渐降低;应用海绵垫干扰本体觉同时,姿势描记仪记录的各参数中,COP 晃动的轨迹长度和平均速度是较适宜描述姿势平衡变化的指标;应用海绵垫对直立人体足底本体觉进行干扰时,应考虑海绵厚度对结果的影响,选择适宜的厚度,以提高其临床应用价值。展开更多
Objective To evaluate efficacy and safety of botulinum toxin type B (BTX-B) in treatment of movement disorders including blepharospasm, oromandibular dystonia, hemifacial spasm, tremor, tics, and hypersecretory disord...Objective To evaluate efficacy and safety of botulinum toxin type B (BTX-B) in treatment of movement disorders including blepharospasm, oromandibular dystonia, hemifacial spasm, tremor, tics, and hypersecretory disorders such as sia-lorrhea and hyperhidrosis. Methods A retrospective study of BTX-B injections in treatment of 58 patients with various neurological disorders was performed. The mean follow-up time was 0.9 ± 0.8 years. Results of the first and last treatment of patients with at least 3 injection sessions were compared. Results The response of 58 patients to a total of 157 BTX-B treatment sessions was analyzed. Of the 157 treatment sessions, 120 sessions (76.4%) resulted in moderate or marked improvement while 17 sessions (10.8%) had no response. The clinical benefits after BTX-B treatment lasted an average of 14 weeks. Of the 41 patients with at least 3 injection ses-sions (mean 10 ± 8.6), most patients needed increased dosage upon the last session compared to the first session. Nineteen patients (32.8%) with 27 sessions (17.2%) reported adverse effects with BTX-B treatment. Conclusions Though most patients require increased dosage to maintain effective response after repeated injections, BTX-B is an effective and safe treatment drug for a variety of movement disorders, as well as drooling and hyperhidrosis.展开更多
文摘目的调查帕金森病（PD）患者中异动症及症状波动的发生率、分布情况以及影响因素。方法详细记录患者资料，并进行统一帕金森病评分量表（UPDRS）、Hoehn＆Yahn（H—Y）分级评分。根据UPDRS1V记录患者有无异动症及症状波动。结果122例患者接受左旋多巴治疗，疗程至少6个月。其中15例（12．3％）合并异动症，41例（33．6％）合并症状波动。异动症的独立影响因素为：发病年龄（OR=0．907，P〈0．01）和左旋多巴总量（95％ CI 1．000～1．004，OR=1．002，P〈0．05）；症状波动的独立影响因素为：发病年龄（OR=0．922，P〈0．05），接受左旋多巴治疗的时间（OR=1．234，P〈0．05），左旋多巴总量（95％ CI 1．002—1．008，OR=1．005，P〈0．01）和H—Y分级（OR=1．869，P〈0．05）。结论本组患者异动症及症状波动的发生率均低于欧洲调查结果，每日左旋多巴总量是异动症及症状波动的独立影响因素。添加其他药物辅助治疗而减少左旋多巴用量，可以减少运动并发症的发生。
文摘目的分析健康人直立于不同厚度海绵垫时姿势特征的变化,探讨本体觉受到不同程度干扰时的姿势平衡改变。方法 30例健康人分别站立于坚硬平板和不同厚度的海绵垫,海绵厚度依次从1到5块,每块厚度4.7 cm。每种站立平面下,均睁眼和闭眼各站立30 s。应用姿势描记仪记录人体直立时足底压力中心(center of pressure,COP)晃动的相关参数,包括总轨迹长、平均速度、单位面积轨迹长、外周面积、实效值面积、矩形面积。结果所有参数在睁眼和闭眼条件下均有随海绵垫厚度的增加而变化趋势(睁眼时 F 值为9.14～107.18,闭眼时 F 值为32.19～144.35,P 值均<0.0001),除单位面积轨迹长呈减少趋势外,其余参数均为增加趋势;对各参数在不同海绵垫间的差异进行比较,无统计学意义的情况有:①总轨迹长和速度:睁眼及闭眼时,4和5块之间;②单位面积轨迹长:睁眼时,0和1、1和3、2和3、3和4、4和5块之间;闭眼时,3和4、3和5、4和5块之间;③外周面积:睁眼时2和3、3和4、4和5块之间;闭眼时,3和4、3和5、4和5块之间;④实效值面积和矩形面积:睁眼时2和3、4和5块之间;闭眼时,3和4、3和5、4和5块之间。其余比较差异均有统计学意义(P<0.05)或极显著统计学意义(P<0.01)。结论在一定范围内,随着海绵垫厚度增加,直立其上的人体本体觉受到的干扰程度加剧,其姿势稳定性逐渐降低;应用海绵垫干扰本体觉同时,姿势描记仪记录的各参数中,COP 晃动的轨迹长度和平均速度是较适宜描述姿势平衡变化的指标;应用海绵垫对直立人体足底本体觉进行干扰时,应考虑海绵厚度对结果的影响,选择适宜的厚度,以提高其临床应用价值。
文摘Objective To evaluate efficacy and safety of botulinum toxin type B (BTX-B) in treatment of movement disorders including blepharospasm, oromandibular dystonia, hemifacial spasm, tremor, tics, and hypersecretory disorders such as sia-lorrhea and hyperhidrosis. Methods A retrospective study of BTX-B injections in treatment of 58 patients with various neurological disorders was performed. The mean follow-up time was 0.9 ± 0.8 years. Results of the first and last treatment of patients with at least 3 injection sessions were compared. Results The response of 58 patients to a total of 157 BTX-B treatment sessions was analyzed. Of the 157 treatment sessions, 120 sessions (76.4%) resulted in moderate or marked improvement while 17 sessions (10.8%) had no response. The clinical benefits after BTX-B treatment lasted an average of 14 weeks. Of the 41 patients with at least 3 injection ses-sions (mean 10 ± 8.6), most patients needed increased dosage upon the last session compared to the first session. Nineteen patients (32.8%) with 27 sessions (17.2%) reported adverse effects with BTX-B treatment. Conclusions Though most patients require increased dosage to maintain effective response after repeated injections, BTX-B is an effective and safe treatment drug for a variety of movement disorders, as well as drooling and hyperhidrosis.
